1. Home >
  2. Apposite Capital Acquires 1MED

M&A Deal Summary

Apposite Capital Acquires 1MED

On May 25, 2021, private equity firm Apposite Capital acquired business services company 1MED

Acquisition Highlights
  • This is Apposite Capital’s 2nd transaction in the Business Services sector.
  • This is Apposite Capital’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2021-05-25
Target 1MED
Sector Business Services
Buyer(s) Apposite Capital
Deal Type Buyout (LBO, MBO, MBI)
Advisor(s) Credit Suisse Investment Banking (Financial)

Target

1MED

Agno, Switzerland
1MED is a specialist CRO that supports the commercialization of new medical technologies and products by providing regulatory strategy, clinical trial management, and quality assurance services across a broad range of therapeutic areas and product types. 1MED was founded in 2014 and is based in Agno, Switzerland.

Search 204,883 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Apposite Capital

London, United Kingdom

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2006
Size Small
Type Sector Focused
DESCRIPTION

Apposite Capital is a private investment firm focused on investing in growth companies in the healthcare sector. The Firm targets UK-based, revenue generating businesses and looks to invest £10 to £25 million over the life of an investment. Specific areas of interest include rehab services, primary and acute care companies, health related software solutions and IT, elderly and specialist healthcare services, medical products, and pharmaceuticals. Apposite Capital was established in 2006 and is based in London.

DEAL STATS #
Overall 14 of 19
Sector (Business Services) 2 of 2
Type (Buyout (LBO, MBO, MBI)) 6 of 10
Country (Switzerland) 1 of 1
Year (2021) 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-24 Emblation

Alloa, United Kingdom

Emblation is designs, manufactures and commercializes next generation microwave-based solutions for a range of skin conditions. The company develops clinically proven technology, SWIFT®, offers a non-ablative, highly effective treatment for common and plantar warts. Emblation’s products are also used in the treatment of certain cancers. Emblation was founded 2007 and is based in Alloa, United Kingdom.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-02 i2a

Montpellier, France

i2a is a provider of instruments, software, and reagents for the clinical microbiology market in France. i2a specializes in offering automated solutions across the value chain of the bacteriology clinical testing market, including Antibiotic Sensitivity Testing which identifies bacterial resistance to antibiotics. i2a was founded in 1988 and is based in Montpellier, France.

Buy -
Mergr

Product

Company

Legal